SCHEMBL4745216

SCHEMBL4745216

CC(C)(C)OC(=O)Oc1ccc(CC(=O)c2cccnc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ELANE P08246 1/20 0.49
KMT2A Q03164 7/20 0.47
LMNA P02545 3/20 0.47
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
PLOD2 O00469 1/20 0.45
PLOD3 O60568 1/20 0.45
PLOD1 Q02809 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ATM Q13315 1/20 0.44
RAB9A P51151 1/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4787680 0.95 THRB (0.46) THRBALDH1A1ELANEKMT2ALMNA
SCHEMBL4744549 0.88 KMT2A (0.54) THRBALDH1A1KMT2ALMNACYP1A2
SCHEMBL4744551 0.82 KMT2A (0.53) THRBALDH1A1KMT2ALMNACYP1A2
SCHEMBL10664827 0.80 KDM4E (0.64) THRBALDH1A1KMT2ALMNAPLOD2
SCHEMBL31326709 0.80 KDM4E (0.64) THRBALDH1A1KMT2ALMNAPLOD2
SCHEMBL6210399 0.77 ELANE (0.51) THRBALDH1A1ELANEKMT2AKDM4E
SCHEMBL8371452 0.76 LMNA (0.68) KMT2ALMNACYP1A2CYP2C9TSHR
SCHEMBL9312108 0.76 RAB9A (0.51) THRBALDH1A1KMT2ALMNACYP1A2
SCHEMBL29861055 0.76 KMT2A (0.55) ALDH1A1KMT2ALMNACYP2C19PLOD2
SCHEMBL2511934 0.76 KMT2A (0.55) ALDH1A1KMT2ALMNACYP2C19PLOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008115141-A1 4, 5-DIHYDRO-1,3-THIAZOL-2-AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY, CARDIOVASCULAR, NEUROLOGICAL OR GASTROINTESTINAL DISORDERS ALBIREO AB (SE) 2008-09-25 WO disclosed